Company news
Waverley Pharma, Inc. (TSXV:WAVE) news
Waverley Pharma, Inc. news releases on 6ix. Latest, Jul 17, 2026: Waverley Pharma Announces Chief Financial Officer Change
Press releases & updates
Waverley Pharma Announces Chief Financial Officer Change
July 17, 2026
Waverley Pharma Acquires US based Pharmacy
September 23, 2024
Waverley Pharma Announces Annual and Special Meeting Election Results
June 20, 2024
Waverley Pharma Business Update
April 30, 2024
Waverley Pharma Announces Changes to Board of Directors
November 22, 2023
Waverley Pharma Provides Business Update
March 20, 2023
Waverley Pharma Provides Update on its PARP-1 Inhibitor Program
January 11, 2023
Waverley Pharma Announces $3,000,000 Credit Facility
August 5, 2021
Waverley Pharma Announces Successful Tender Award for Pemetrexed with NHS England
May 27, 2021
Waverley Pharma Announces Successful Tender Award for Capecitabine with NHS Scotland
January 18, 2021
Waverley Pharma Announces Tentative ANDA Approval for Pemetrexed in the United States
November 12, 2020
Waverley Pharma Announces Listing on the Frankfurt Stock Exchange (FSE: 5GZ)
September 23, 2020
Waverley Pharma Announces Signing of Term Sheet to Acquire Exclusive Rights to Market Six Generic Oncology Products in the United States
September 8, 2020
Waverley Pharma Announces Grant of Market Authorization for Pemetrexed in Spain and Bortezomib in Italy
August 25, 2020
Waverley Pharma Announces Grant of Market Authorization for Pemetrexed and Bortezomib in Multiple European Countries
July 30, 2020
Waverley Pharma Announces Collaboration with Dr. David E. Herbert and the University of Manitoba for the Development of a Synthetic Library of Chloroquine Analogs to Treat COVID-19
June 25, 2020
Waverley Pharma Announces Reliance on Relief from Filing Requirements for Annual Financial Statements
April 28, 2020
Waverley Pharma Announces Appointment of New President and CEO
February 3, 2020
Waverley Pharma Announces Executive Leadership Changes
January 8, 2020
Waverley Pharma Announces Grant of Marketing Authorization in the United Kingdom for Erlotinib
December 17, 2019
Waverley Pharma Provides Market Update and Fiscal 2018 Preliminary Revenue
March 11, 2019
Waverley Pharma Announces Distribution Agreement and First Sale of Generic Oncology Products in the United Kingdom
December 18, 2018
Waverley Pharma Announces Resignation of CEO and Appointment of New CEO
July 23, 2018
Waverley Pharma Announces Filing of Two Abbreviated New Drug Applications in the United States
June 27, 2018
Waverley Pharma Announces Acquisition of two Generic Oncology Products Currently Marketed in the United Kingdom
June 25, 2018
Waverley Pharma Announces Filing of its Second Marketing Authorization Application in Select European Union Countries
April 17, 2018
Waverley Pharma Announces Filing of Marketing Authorization Application in Select European Union Countries
March 12, 2018
IIROC Trading Resumption - WAVE (Formerly BUFF.P)
October 27, 2017
IIROC Trade Resumption - Waverley Pharma Inc.
October 27, 2017
Buffalo Capital Inc. announces amendment to amalgamation agreement and confirms October 6, 2017 shareholder meeting date
September 20, 2017
Buffalo Capital Inc. announces mailing of information circular and provides transaction update
September 15, 2017
Buffalo Capital Inc. Announces Its Qualifying Transaction and a Concurrent Financing
August 9, 2017
IIROC Trade Halt - BUFFALO CAPITAL INC.
August 8, 2017
IIROC Trading Halt - BUFF.P
August 8, 2017
IIROC Trading Resumption - BUFF.P; DVC.H; HVST
April 27, 2017
IIROC Trade Resumption - BUFFALO CAPITAL INC.
April 27, 2017
Buffalo Capital Inc. Announces Closing of Initial Public Offering
April 27, 2017